Abstract B022: A Living Biobank and Functional Precision Oncology Platform for Rare Cancers
Using this integrated platform, novel and potentially actionable therapeutic vulnerabilities across multiple rare cancers are identified, including sensitivity to CDK4/6 inhibition in rare bladder cancer, PLK1 inhibition in fibrolamellar carcinoma, and synergistic targeting of MEK and YAP signaling in solitary fibrous...